The Effect of Dopaminergic Blockade on Thyrotrophin Response to Thyrotrophin-Releasing Hormone and Somatostatin

A. Sánchez; E. Montoya

doi:10.1055/s-2007-1011890

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 1987; 19(12): 604-605
DOI: 10.1055/s-2007-1011890

ORIGINALS

Basic
© Georg Thieme Verlag, Stuttgart · New York

The Effect of Dopaminergic Blockade on Thyrotrophin Response to Thyrotrophin-Releasing Hormone and Somatostatin

A. Sánchez¹ , E. Montoya²

¹Departamento de Investigación, Centro Ramón y Cajal de la Seguridad Social, Madrid, Spain
²Departamento de Biología y Bioquímica, Facultad de Ciencias, Universidad de Cádiz, Puerto Real, Cádiz, Spain

Abstract

PDF Download

Summary

Using a large number of animals we have been able to demonstrate that somatostatin administration (20 μg/100 g bw) significantly reduces both basal serum thyrotrophin (TSH) levels and the response to thyrotrophin-releasing hormone (TRH) in the normal rat. Pretreatment with the dopaminergic antagonist domperidone resulted in increased TSH levels, increased response to TRH but no modification in the response to somatostatin.

Key-Words

TSH - TRH - Somatostatin - Domperidone

PDF (187 kb)